Company profile
Shattuck Labs, Inc.
Pipeline2 assets
- SL-325SL-325 / DR3 (Death Receptor 3) / Monoclonal Antibody / Inflammatory and Immune-Mediated DiseasesInflammatory Bowel Disease (IBD)Crohn's DiseaseUlcerative Colitis
- SL-425SL-425 / DR3 (Death Receptor 3) / Monoclonal Antibody / Inflammatory and Immune-Mediated DiseasesInflammatory Bowel Disease (IBD)
Latest news9 items
All newsShattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Results Call • Phase 1Results call Mon, Jun 8, 2026